leadf
logo-loader
view22nd Century Group Inc

22nd Century climbs on record sales and surprise profit in 1Q

The New York-based group turned a surprise profit in the first quarter thanks to the recognition of an unrealised gain on its investment in Anandia Laboratories of US$6mln

tobacco plants
22nd Century’s technology allows it to control the amount of nicotine in tobacco plants

Shares in 22nd Century Group Inc (NYSE:XXII) zipped higher after the bell on Thursday as the biotech posted another record quarter of sales.

The Clarence, New York-based company, which has developed a technology to regulate the levels of nicotine in tobacco plants, recorded net sales of US$6.12mln (1Q 17: US$2.23mln) the first three months of 2018.

The increase in net sales revenue was primarily the result of continued additional sales generated from a filtered cigar manufacturing agreement which began last spring.

22nd Century also managed to turn a profit thanks to the recognition of an unrealised gain on its investment in Anandia Laboratories of US$6mln.

For the quarter, the firm recorded net income of US$0.01 per share, compared to a net loss of US$0.03 per share in the year-ago period.

That surprise profit came despite a sharp increase in spending on securing regulatory approvals for its very low nicotine cigarettes.

The company had more than US$59mln in cash and short-term investments, which are sufficient reserves to meet regular operating expenses for a number of years.

Using its technology, 22nd Century has been able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels.

The company says its very low nicotine tobacco has proven to be a very effective tool in helping those trying to give up smoking.

For smokers who do not want to quit, 22nd Century’s high nicotine tobacco enables it to produce a cigarette with what is claims is the world’s lowest tar-to-nicotine ratio.

Quick facts: 22nd Century Group Inc

Price: 1.43 USD

NYSE:XXII
Market: NYSE
Market Cap: $193.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Vox Royalties' snaps up Bushvelds' Brits Vanadium Project as second...

Proactive London's Ryan Long explains the strategy behind Vox Royalties' (CVE:VOX) acquiring royalty on Bushveld's Brits Vanadium Project. This is hot on the heels of the acquisition of a portfolio of royalties in North America earlier this month. The total consideration for the...

58 minutes ago

2 min read